Skip to main content
DrugPrice

Out-of-Pocket Cost

The amount a patient pays directly for a prescription drug, including copays, coinsurance, and deductible payments.

How It Works

Out-of-pocket (OOP) costs in U.S. drug coverage vary by more than three orders of magnitude depending on insurance, drug tier, and coverage phase. A Tier 1 generic like lisinopril may cost $0-5 per fill on a Medicare Advantage plan; a Tier 5 specialty like Ibrance (palbociclib) at roughly $15,000/month with 33% coinsurance previously cost patients $5,000+ in the initial phase before the IRA cap. The 2025 Part D OOP cap of $2,000 is the most significant patient financial protection in Part D's history and is funded by the redesigned plan/manufacturer/Medicare liability shares in the catastrophic phase. The IRA also capped insulin copays at $35/month for all covered insulin products starting January 1, 2023, and eliminated vaccine cost-sharing for all ACIP-recommended adult vaccines in Part D (shingles, Tdap, etc.). For commercial insurance, OOP costs are capped annually by the ACA maximum out-of-pocket limit ($9,450 individual / $18,900 family for 2024), but that cap includes medical costs, not just drugs. Patients can reduce OOP further through manufacturer copay cards (commercial patients only, prohibited in Medicare/Medicaid under anti-kickback rules), patient assistance programs, drug discount cards like GoodRx, Cost Plus Drugs for generics, and 340B discounted pricing at qualifying hospital outpatient pharmacies. State drug affordability boards (Colorado, Maryland, Oregon, Washington, Minnesota, Maine, New Hampshire) are beginning to set upper payment limits on selected drugs.

Related Terms

  • Medicare Part D Redesign (2025), The IRA-mandated restructuring of Medicare Part D, effective January 1, 2025, that caps annual out-of-pocket drug spending at $2,000 and shifts cost-sharing liability among plans, manufacturers, and government.
  • Copay Assistance, Financial help from manufacturers, foundations, or pharmacies that reduces a patient's out-of-pocket cost for a specific drug, typically via copay cards, coupons, or charitable grants.
  • Formulary, A list of prescription drugs covered by an insurance plan, organized into tiers that determine how much the patient pays for each drug.
  • Donut Hole (Coverage Gap), A phase in Medicare Part D where patients historically paid a higher share of drug costs after exceeding initial coverage but before reaching catastrophic coverage.

Explore Drug Data

Most Expensive DrugsGeneric Drug WatchSearch All Drugs

About This Definition

This definition is part of the DrugPrice Drug Pricing Glossary, 49 terms explaining how prescription drug pricing works in the United States. All definitions are written in plain language for patients, caregivers, journalists, and healthcare professionals.

this entity is one of the U.S. Medicare prescription-drug pricing concepts that recurs across this site. The definition above is the technical answer; the paragraphs below add the practical context for how the concept connects to the CMS Medicare Part D Drug Spending data data behind every per-entity page on the site.

In the CMS Medicare Part D Drug Spending data data, this concept shapes one or more of the fields that drive the per-entity grades and rankings on this site. The methodology page describes which fields feed into which output; this glossary entry documents the underlying term.

Source: CMS Medicare Part D Spending, 2026.